Epitomee Medical Ltd (EPIT) - Net Assets
Based on the latest financial reports, Epitomee Medical Ltd (EPIT) has net assets worth ILA30.72 Million ILA (≈ $82.35K USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA37.04 Million ≈ $99.31K USD) and total liabilities (ILA6.32 Million ≈ $16.95K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore EPIT current and non-current assets for the complete picture of this company's asset base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA30.72 Million |
| % of Total Assets | 82.93% |
| Annual Growth Rate | 64.58% |
| 5-Year Change | 753.71% |
| 10-Year Change | N/A |
| Growth Volatility | 461.33 |
Epitomee Medical Ltd - Net Assets Trend (2018–2024)
This chart illustrates how Epitomee Medical Ltd's net assets have evolved over time, based on quarterly financial data. Check EPIT goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Annual Net Assets for Epitomee Medical Ltd (2018–2024)
The table below shows the annual net assets of Epitomee Medical Ltd from 2018 to 2024. For live valuation and market cap data, see EPIT company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA33.95 Million ≈ $91.02K |
-2.44% |
| 2023-12-31 | ILA34.80 Million ≈ $93.30K |
-11.78% |
| 2022-12-31 | ILA39.45 Million ≈ $105.75K |
-25.99% |
| 2021-12-31 | ILA53.30 Million ≈ $142.89K |
+1240.16% |
| 2020-12-31 | ILA3.98 Million ≈ $10.66K |
-42.32% |
| 2019-12-31 | ILA6.89 Million ≈ $18.49K |
+303.93% |
| 2018-12-31 | ILA1.71 Million ≈ $4.58K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Epitomee Medical Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4071100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ILA816.00K | 2.40% |
| Other Components | ILA94.16 Million | 277.32% |
| Total Equity | ILA33.95 Million | 100.00% |
Epitomee Medical Ltd Competitors by Market Cap
The table below lists competitors of Epitomee Medical Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Andromeda Metals Ltd
AU:ADN
|
$26.17 Million |
|
Thai O.P.P. Public Company Limited
BK:TOPP
|
$26.18 Million |
|
China Crystal New Material
KQ:900250
|
$26.19 Million |
|
Renovaro Biosciences Inc
NASDAQ:RENB
|
$26.19 Million |
|
CompuLab Ltd
TA:CLAB
|
$26.17 Million |
|
Duc Long Gia Lai Group JSC
VN:DLG
|
$26.16 Million |
|
ilShinbiobase Co. Ltd
KQ:068330
|
$26.14 Million |
|
Black Dragon Gold Corp
AU:BDG
|
$26.12 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Epitomee Medical Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 34,800,000 to 33,952,000, a change of -848,000 (-2.4%).
- Net loss of 5,324,860 reduced equity.
- New share issuances of 11,000 increased equity.
- Other comprehensive income decreased equity by 377,000.
- Other factors increased equity by 4,842,860.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-5.32 Million | -15.68% |
| Share Issuances | ILA11.00K | +0.03% |
| Other Comprehensive Income | ILA-377.00K | -1.11% |
| Other Changes | ILA4.84 Million | +14.26% |
| Total Change | ILA- | -2.44% |
Book Value vs Market Value Analysis
This analysis compares Epitomee Medical Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 284.62x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 1386.75x to 284.62x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | ILA0.23 | ILA324.60 | x |
| 2020-12-31 | ILA0.14 | ILA324.60 | x |
| 2021-12-31 | ILA1.81 | ILA324.60 | x |
| 2022-12-31 | ILA4.71 | ILA324.60 | x |
| 2023-12-31 | ILA1.18 | ILA324.60 | x |
| 2024-12-31 | ILA1.14 | ILA324.60 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Epitomee Medical Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -15.68%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.18x
- Recent ROE (-15.68%) is above the historical average (-32.49%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -50.60% | 0.00% | 0.00x | 1.12x | ILA-4.18 Million |
| 2020 | -79.63% | 0.00% | 0.00x | 5.36x | ILA-3.56 Million |
| 2021 | -21.61% | 0.00% | 0.00x | 1.24x | ILA-16.85 Million |
| 2022 | -11.10% | 0.00% | 0.00x | 0.40x | ILA-29.26 Million |
| 2023 | -16.33% | -56.82% | 0.25x | 1.16x | ILA-9.16 Million |
| 2024 | -15.68% | 0.00% | 0.00x | 1.18x | ILA-8.72 Million |
Industry Comparison
This section compares Epitomee Medical Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $52,941,889
- Average return on equity (ROE) among peers: -24.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Epitomee Medical Ltd (EPIT) | ILA30.72 Million | -50.60% | 0.21x | $26.17 Million |
| Allmed Solutions Ltd (ALMD) | $52.31 Million | 5.37% | 0.05x | $8.17 Million |
| Erika Carmel Ltd (BCUR) | $42.67 Million | -76.32% | 0.60x | $4.69 Million |
| Bio-View Ltd (BIOV) | $16.69 Million | 8.64% | 0.79x | $20.36 Million |
| Brainsway Ltd (BWAY) | $10.29 Million | -23.30% | 0.94x | $533.52 Million |
| Erech Finance Cahalacha Ltd (EFNC) | $-1.48 Million | 0.00% | 0.00x | $1.61 Million |
| Erika Carmel-Tech Ltd (ERKA) | $9.79 Million | -59.80% | 1.98x | $5.65 Million |
| Human Xtensions Ltd (HUMX) | $104.53 Million | -51.30% | 0.15x | $2.12 Million |
| Ilex Medical (ILX) | $109.44 Million | 17.00% | 0.55x | $145.48 Million |
| Pulsenmore Ltd (PULS) | $132.23 Million | -44.29% | 0.36x | $22.89 Million |
About Epitomee Medical Ltd
Epitomee Medical Ltd, a biomedical company, develops and commercializes ingestible therapeutic devices worldwide. It offers capsules, which are polymer-based scaffold for controlled delivery of therapies along the GI tract for weight management and biologics delivery. The company was incorporated in 2005 and is based in Caesarea, Israel.